79913-44-3

Upstream product

• 52-67-5 3,3-dimethyl-D-cysteine 
• 100-52-7 benzaldehyde 
• 108-24-7 acetic anhydride 
• 280108-25-0 2(R,S)-phenyl-5,5-dimethylthiazolidine-4(S)-carboxylic acid 
• 109132-33-4 2S,4S-2-phenyl-5,5-dimethylthiazolidine-4-carboxylic acid 
• 52-66-4 D-(-)-penicillamine 

Downstream Products

• 79913-46-5 3-acetyl-2(S)-phenyl-5,5-dimethylthiazolidine-4(R)-carboxylic acid 
• 116476-04-1 (-)-(2S)-3-acetyl-2-<2-<(2S,4S)-3-acetyl-5,5-dimethyl-2-phenylthiazolidin-4-ylcarbonyloxy>-5-methoxyphenyl>benzothiazoline 
• 123011-60-9 (+)-(2R)-3-acetyl-2-<2-<(2S,4S)-3-acetyl-5,5-dimethyl-2-phenylthiazolidin-4-ylcarbonyloxy>-5-methoxyphenyl>benzothiazoline 

Relevant academic research and scientific papers

KAPPA-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE

The present invention provides κ opioid receptor agonists comprising 2-phenylbenzothiazoline derivatives. The present invention relates to κ opioid receptor agonists comprising compounds or salts thereof having the chemical structure represented by the ge

Synthesis and Characterisation ot Diastereomeric (4S)-3-Acetyl-2-aryl-5,5-dimethyl-4-thiazolidinecarboxylic Acids

The condensation of aromatic aldehydes 1 and D-penicillamine (2) in aqueous methanol gives (4S)-2-aryl-5,5-dimethyl-4-thiazolidinecarboxylic acids 3 with alternating diastereoselectivity in position 2.Acetylation of the products with acetic anhydride in pyridine or in water gives rise to (2S,4S)-3-acetyl-2-aryl-5,5-dimethyl-4-thiazolidinecarboxylic acids 5.Use of a HCl/dioxane system in the reaction of N-acetyl-D-penicillamine (6) with aldehydes made possible the effective preparation of (2R,4S) compounds 8.The diastereommeric compounds 5 and 8 were characterized by (1)H- and (13)C-NMR data and optical rotation and CD.The results were compared with those compiled from the already synthesized diastereomeric (4R)-3-acetyl-2-aryl-4-thiazolidinecarboxylic acids.

Thiazolidinecarboxylic acid derivatives and treatment of liver diseases therewith

The invention relates to novel thiazolidine-4(S)-carboxylic acid derivatives of the general formula (I) STR1 wherein R1 stands for an optionally substituted furyl, pyrrolyl, thienyl, benzofuryl, benzopyrrolyl, benzothienyl, phenyl, pyridyl, quinolinyl, isoquinolinyl or indanyl group or a C1-4 alkyl or C2-4 alkenyl group optionally substituted by a hydroxyl, carboxyl or halogen fenoxy group, stands for hydrogen, an alkaline metal or an alkaline earth metal atom or an optionally substituted C1-4 alkyl group or aryl group; R3 represents hydrogen or an optionally substituted C1-4 alkyl or acyl group or aryl group as well as their salts. Further on, the invention relates to pharmaceutical preparations containing these compounds and to a process for preparing these compounds and preparations. The compounds of the invention are useful for treating or preventing liver damages of either natural or experimental origin.